Document is current
Any future updates will be listed below
-
Authors
Park, Ko Un
Delisle, Megan
Hassett, Michael J.
Minami, Christina A.
Punglia, Rinaa S.
Woodbury, Samuel R.
Brindle, Mary
Mittendorf, Elizabeth A.
King, Tari A.
-
Funding
Funding for this research was provided by:
National Cancer Institute (K08CA263488)
- License Information
-
More Information
Article History
Received: 23 February 2026
Accepted: 30 April 2026
First Online: 14 May 2026
Ethics
Disclosure: EAM reports compensated service on scientific advisory boards for Astra Zeneca, BioNTech, Merck and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; institutional research support from Roche/Genentech (via SU2C grant) and Gilead; research funding from Susan Komen for the Cure for which she serves as a scientific advisor; and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. TAK reports speaker honoraria for Exact Sciences, compensated service on the FES Steering Committee for GE Healthcare, compensated service for a Prosigna advisory board role for Veracyte, compensated service on the advisory board for Ataraxia AI, and compensated service as faculty for PrecisCa cancer information service.
Prior presentation: Presented in part as a poster at the 2025 San Antonio Breast Cancer Symposium.
